## Maurizio Martini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5391988/publications.pdf

Version: 2024-02-01

234 papers

6,781 citations

50276 46 h-index 91884 69 g-index

235 all docs

235
docs citations

times ranked

235

10388 citing authors

#	Article	IF	CITATIONS
1	Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach. Journal of Neurosurgical Sciences, 2023, 67, .	0.6	5
2	Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples. Journal of Clinical Pathology, 2023, 76, 671-677.	2.0	1
3	Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunology, Immunotherapy, 2022, 71, 45-55.	4.2	39
4	Evaluating programmed deathâ€ligand 1 (PDâ€L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Histopathology, 2022, 80, 397-406.	2.9	21
5	The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma Urologic Oncology: Seminars and Original Investigations, 2022, 40, 108.e19-108.e25.	1.6	8
6	Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Diagnostics, 2022, 12, 477.	2.6	10
7	A multi-surgeon learning curve analysis of overall and site-specific positive surgical margins after RARP and implications for training. Journal of Robotic Surgery, 2022, , 1.	1.8	5
8	Molecular Analysis in a Glioblastoma Cohortâ€"Results of a Prospective Analysis. Journal of Personalized Medicine, 2022, 12, 685.	2.5	5
9	PD‣1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside. Clinical and Experimental Dental Research, 2022, 8, 690-698.	1.9	18
10	A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights. International Journal of Molecular Sciences, 2022, 23, 7872.	4.1	0
11	Methylation study of the Paris system for reporting urinary (TPS) categories. Journal of Clinical Pathology, 2021, 74, 102-105.	2.0	7
12	Neuroimages and Neuropathology of a Stroke-Like Cerebral Lymphomatoid Granulomatosis. Canadian Journal of Neurological Sciences, 2021, 48, 114-115.	0.5	0
13	The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 131.e17-131.e21.	1.6	10
14	Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process. Medical Molecular Morphology, 2021, 54, 187-191.	1.0	6
15	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinomaâ€, Journal of Pathology Informatics, 2021, 12, 1.	1.7	22
16	ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biology, 2021, 22, 51.	8.8	71
17	The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. International Journal of Molecular Sciences, 2021, 22, 1877.	4.1	12
18	Pericardial metastasis from alveolar rhabdomyosarcoma: A case report. Diagnostic Cytopathology, 2021, 49, E297-E300.	1.0	1

#	Article	IF	CITATIONS
19	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.6	O
20	Dilation of Brain Veins and Perivascular Infiltration by Glioblastoma Cells in an In Vivo Assay of Early Tumor Angiogenesis. BioMed Research International, 2021, 2021, 1-11.	1.9	1
21	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). Cancers, 2021, 13, 2098.	3.7	5
22	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Frontiers in Oncology, 2021, 11, 650293.	2.8	26
23	Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. Cancers, 2021, 13, 2148.	3.7	8
24	How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquidâ€based cytology: Role of TERT promoter and BRAF V600E mutation analysis. Cancer Cytopathology, 2021, 129, 819-829.	2.4	12
25	The Role of Cytology in the Diagnosis of Subcentimeter Thyroid Lesions. Diagnostics, 2021, 11, 1043.	2.6	6
26	Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. Journal of Experimental and Clinical Cancer Research, 2021, 40, 228.	8.6	45
27	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2021, 22, 351-360.	2.6	7
28	Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. Human Pathology, 2021, 118, 42-48.	2.0	11
29	Clear cell endometrial carcinoma precursors: presentation of two cases and diagnostic issues. Diagnostic Pathology, 2021, 16, 95.	2.0	5
30	Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. Diagnostics, 2021, 11, 10.	2.6	13
31	Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica, 2021, 106, 3162-3169.	3.5	4
32	Targeting the mitogenâ€'activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in lowâ€'grade glioma cells. Oncology Reports, 2021, 45, 752-763.	2.6	1
33	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. Acta Neuropathologica Communications, 2021, 9, 200.	5.2	10
34	Cytological features of micropapillary and plasmacytoid variants of urothelial carcinoma. Diagnostic Cytopathology, 2020, 48, 111-117.	1.0	9
35	The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). Leukemia and Lymphoma, 2020, 61, 1133-1139.	1.3	6
36	Pleural metastasis from auricular melanoma: A brief report. Diagnostic Cytopathology, 2020, 48, 376-379.	1.0	5

#	Article	IF	CITATIONS
37	PDâ€L1 and thyroid cytology: A possible diagnostic and prognostic marker. Cancer Cytopathology, 2020, 128, 177-189.	2.4	13
38	Brain Invasion along Perivascular Spaces by Glioma Cells: Relationship with Blood–Brain Barrier. Cancers, 2020, 12, 18.	3.7	19
39	CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. Cancers, 2020, 12, 1922.	3.7	7
40	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, $1$ , $10$ - $22$ .	0.6	0
41	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.6	0
42	Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (IncRNA) NEAT1. International Journal of Molecular Sciences, 2020, 21, 3610.	4.1	25
43	Deregulated expression of the imprinted <i>DLK1-DIO3</i> region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro-Oncology, 2020, 22, 1771-1784.	1.2	44
44	Prevalence of <scp>PD‣1</scp> expression in head and neck squamous precancerous lesions: a systematic review and metaâ€analysis. Head and Neck, 2020, 42, 3018-3030.	2.0	23
45	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. Cancers, 2020, 12, 638.	3.7	52
46	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 269-277.	2.8	13
47	Biomarkers of response to advanced prostate cancer therapy. Expert Review of Molecular Diagnostics, 2020, 20, 195-205.	3.1	12
48	A Risk Score Based on 5 Clinico-Pathological Variables Predicts Recurrence of Atypical Meningiomas. Journal of Neuropathology and Experimental Neurology, 2020, 79, 500-507.	1.7	14
49	Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report. BMC Cancer, 2019, 19, 763.	2.6	1
50	A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. Cancers, 2019, 11, 848.	3.7	38
51	First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. Frontiers in Endocrinology, 2019, 10, 365.	3.5	1
52	Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. Frontiers in Endocrinology, 2019, 10, 619.	3.5	7
53	Germ Cell Neoplasia in situ (GCNIS) in Testis-Sparing Surgery (TSS) for Small Testicular Masses (STMs). Frontiers in Endocrinology, 2019, 10, 512.	3.5	4
54	A large series of hyalinizing trabecular tumors: Cytomorphology and ancillary techniques on fine needle aspiration. Cancer Cytopathology, 2019, 127, 390-398.	2.4	11

#	Article	IF	CITATIONS
55	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. Frontiers in Oncology, 2019, 9, 232.	2.8	31
56	The immunocytochemical expression of VE â€1 (BRAF V600Eâ€related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquidâ€based cytology. Cytopathology, 2019, 30, 460-467.	0.7	12
57	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	7.0	67
58	Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. Genome Biology, 2019, 20, 33.	8.8	49
59	BS48â€Microrna editing is integral for interleukin-6 trans-signalling and leukocyte trafficking to ischemic tissues. , 2019, , .		0
60	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European Journal of Cancer, 2019, 107, 164-174.	2.8	9
61	Glioblastoma endothelium drives bevacizumabâ€induced infiltrative growth <i>via</i> modulation of PLXDC1. International Journal of Cancer, 2019, 144, 1331-1344.	5.1	22
62	Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. Clinical Epigenetics, 2019, 11, 2.	4.1	15
63	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. Pathology and Oncology Research, 2019, 25, 513-520.	1.9	5
64	34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 306-310.	1.2	3
65	Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study) Journal of Clinical Oncology, 2019, 37, 3554-3554.	1.6	0
66	Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis Journal of Clinical Oncology, 2019, 37, e15038-e15038.	1.6	0
67	To Obtain More With Less: Cytologic Samples With Ancillary Molecular Techniquesâ€"The Useful Role of Liquid-Based Cytology. Archives of Pathology and Laboratory Medicine, 2018, 142, 299-307.	2.5	22
68	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood, 2018, 131, 2413-2425.	1.4	223
69	Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. Modern Pathology, 2018, 31, 1361-1366.	5.5	29
70	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features in the pediatric age group. Cancer Cytopathology, 2018, 126, 27-35.	2.4	28
71	The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 324-329.	1.2	4
72	Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. International Journal of Molecular Sciences, 2018, 19, 3948.	4.1	36

#	Article	IF	CITATIONS
73	Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. Molecular Diagnosis and Therapy, 2018, 22, 723-728.	3.8	12
74	Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. Acta Neurochirurgica, 2018, 160, 2387-2391.	1.7	2
75	Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. Apmis, 2018, 126, 705-709.	2.0	15
76	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. Anticancer Research, 2018, 38, 3789-3796.	1.1	64
77	Plexiform architecture in gastrointestinal stromal tumors is not restricted to succinate dehydrogenase-deficient cases. Human Pathology: Case Reports, 2018, 13, 69-72.	0.2	1
78	VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. BMC Cancer, 2018, 18, 553.	2.6	11
79	Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death and Disease, 2018, 9, 841.	6.3	182
80	Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. Oncotarget, 2018, 9, 9325-9343.	1.8	30
81	Morphological features that can predict <i>BRAF</i> <sup><i>V600E</i></sup> â€mutated carcinoma in paediatric thyroid cytology. Cytopathology, 2017, 28, 55-64.	0.7	11
82	SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. Prostate, 2017, 77, 597-603.	2.3	4
83	A threeâ€microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes. Molecular Oncology, 2017, 11, 1115-1129.	4.6	32
84	New Insight in a New Entity: NIFTPS and Valuable Role of Ancillary Techniques. The Role of PD-L1. EBioMedicine, 2017, 18, 11-12.	6.1	5
85	When Somatic Mutations Are Associated With a Higher Aggressive Behavior—A Story of Announced Evidence. JAMA Oncology, 2017, 3, 1427.	7.1	0
86	The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro-Oncology, 2017, 19, 1097-1108.	1.2	56
87	The role of miRNAs in the evaluation of follicular thyroid neoplasms: an overview of literature. Journal of the American Society of Cytopathology, 2017, 6, 96-104.	0.5	3
88	Cytopathology of Follicular Cell Nodules. Advances in Anatomic Pathology, 2017, 24, 45-55.	4.3	11
89	Novel <i>SEC61G</i> ê° <i>EGFR</i> Fusion Gene in Pediatric Ependymomas Discovered by Clonal Expansion of Stem Cells in Absence of Exogenous Mitogens. Cancer Research, 2017, 77, 5860-5872.	0.9	21
90	The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature. Cancer Cytopathology, 2017, 125, 594-603.	2.4	16

#	Article	IF	CITATIONS
91	The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation. Endocrine, 2017, 56, 379-387.	2.3	0
92	Discordance in RAS Mutations between Primary Colon Tumor and Metastases: A Real Event or a Matter of Methodology?. International Journal of Biological Markers, 2017, 32, 474-477.	1.8	2
93	Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. Journal of Gastrointestinal Oncology, 2017, 8, E4-E9.	1.4	0
94	Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results. Journal of Clinical Oncology, 2017, 35, 2133-2140.	1.6	178
95	The Role of Liquid Based Cytology and Ancillary Techniques in the Peritoneal Washing Analysis: Our Institutional Experience. PLoS ONE, 2017, 12, e0168625.	2.5	18
96	Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. Oncotarget, 2017, 8, 3746-3760.	1.8	8
97	Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget, 2017, 8, 13223-13239.	1.8	30
98	A phase 2 study of temozolomide in patients affected by pretreated metastatic colorectal cancer with MGMT promoter methylation Journal of Clinical Oncology, 2017, 35, 629-629.	1.6	1
99	Adequacy of EBUS-TBNA specimens for molecular testing in lung adenocarcinoma. , 2017, , .		0
100	Divergent gastrointestinal stromal tumors in syndromic settings. Cancer Genetics, 2016, 209, 354-358.	0.4	10
101	Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive. Journal of Clinical Oncology, 2016, 34, e107-e109.	1.6	5
102	The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms. Endocrine, 2016, 54, 723-732.	2.3	36
103	Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features on liquidâ€based cytology: Some insights into their identification. Cancer Cytopathology, 2016, 124, 699-710.	2.4	78
104	CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Medicine, 2016, 5, 398-406.	2.8	28
105	The potential of liquidâ€based cytology in lymph node cytological evaluation: the role of morphology and the aid of ancillary techniques. Cytopathology, 2016, 27, 50-58.	0.7	10
106	Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Scientific Reports, 2016, 6, 21557.	3.3	75
107	Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor. Medicine (United) Tj ETQq $1\ 1$	0.784314 1.0	rgBT /Overlo
108	Gastrointestinal stromal tumors (GISTs) and second malignancies. Medicine (United States), 2016, 95, e4718.	1.0	11

#	Article	IF	CITATIONS
109	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. Molecular Diagnosis and Therapy, 2016, 20, 55-63.	3.8	22
110	Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. Thrombosis Research, 2016, 141, 106-111.	1.7	34
111	Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. Stroke, 2016, 47, 886-890.	2.0	52
112	Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical and Translational Oncology, 2016, 18, 988-995.	2.4	16
113	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. Molecular Diagnosis and Therapy, 2016, 20, 65-74.	3.8	7
114	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 628-634.	1.3	24
115	c-Myc expression as a key-marker in the colorectal cancer resistance to EGFR inhibitors Journal of Clinical Oncology, 2016, 34, e15034-e15034.	1.6	3
116	The role of fine-needle aspiration in the thyroid nodules of elderly patients. Oncotarget, 2016, 7, 11850-11859.	1.8	9
117	ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. Oncotarget, 2016, 7, 35159-35168.	1.8	14
118	SOCS3 immunohistochemical expression to support the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system Journal of Clinical Oncology, 2016, 34, 216-216.	1.6	0
119	Translational impact of patient-derived glioblastoma tumorspheres Journal of Clinical Oncology, 2016, 34, 2025-2025.	1.6	0
120	Uncommon <i>BRAF</i> mutations in the follicular variant of thyroid papillary carcinoma: New insights. Cancer Cytopathology, 2015, 123, 593-602.	2.4	22
121	Is thyroid gland only a "land―for primary malignancies? role of morphology and immunocytochemistry. Diagnostic Cytopathology, 2015, 43, 374-380.	1.0	19
122	Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. BioMed Research International, 2015, 2015, 1-10.	1.9	50
123	Well-differentiated Thyroid Cancer With a Minor Poorly Differentiated Component. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 196-201.	1.2	3
124	PDGFRA-mutant syndrome. Modern Pathology, 2015, 28, 954-964.	5 <b>.</b> 5	50
125	A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. European Journal of Human Genetics, 2015, 23, 1673-1678.	2.8	15
126	Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia. Neoplasia, 2015, 17, 401-409.	<b>5.</b> 3	24

#	Article	IF	CITATIONS
127	Endoscopic ultrasound-guided fine needle tissue acquisition biopsy samples do not allow a reliable proliferation assessment of gastrointestinal stromal tumours. Digestive and Liver Disease, 2015, 47, 291-295.	0.9	18
128	VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. Neurology, 2015, 84, 1906-1908.	1.1	22
129	High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumourâ€initiating properties of colon cancer stem cells. Journal of Pathology, 2015, 236, 479-490.	4.5	47
130	Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer Journal, 2015, 5, e323-e323.	6.2	32
131	Pituitary-tumour-transforming-gene 1 expression in testicular cancer. Andrologia, 2015, 47, 427-432.	2.1	17
132	Gemcitabine versus FOLFIRINOX in patients with advanced hENT1 <sup>+ve</sup> pancreatic adenocarcinoma Journal of Clinical Oncology, 2015, 33, e15295-e15295.	1.6	1
133	The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology. PLoS ONE, 2015, 10, e0132939.	2.5	21
134	miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Oncotarget, 2015, 6, 37241-37256.	1.8	42
135	Pyrosequencing evaluation of low-frequency <i>KRAS</i> mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. Future Oncology, 2014, 10, 713-723.	2.4	10
136	Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor. Neuropathology, 2014, 34, 179-184.	1.2	12
137	The role of thyroid fineâ€needle aspiration cytology in the pediatric population: An institutional experience. Cancer Cytopathology, 2014, 122, 359-367.	2.4	26
138	Holoinspiratory Wheezing in a 46-Year-Old HIV-Seropositive Man. Clinical Infectious Diseases, 2014, 58, 134-135.	5.8	1
139	Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker. Journal of Molecular Diagnostics, 2014, 16, 467-476.	2.8	16
140	Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience. Cancer Cytopathology, 2014, 122, 527-535.	2.4	47
141	Thyroglossal duct cyst cancer most likely arises from a thyroid gland remnant. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 67-72.	2.8	22
142	Papillary thyroid microcarcinoma: a painstaking category to manage. Clinical Endocrinology, 2014, 81, 785-786.	2.4	3
143	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood, 2014, 123, 3677-3679.	1.4	22
144	Morphological parameters able to predict <scp><i>BRAF<sup>V600E</sup></i></scp> â€mutated malignancies on thyroid fineâ€needle aspiration cytology: Our institutional experience. Cancer Cytopathology, 2014, 122, 883-891.	2.4	39

#	Article	IF	Citations
145	Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. Blood Transfusion, 2014, 12 Suppl 1, s367-74.	0.4	17
146	Abnormal Mirna Expression Profile and Cytokine Production in Myelodysplastic Vascular Niche. Blood, 2014, 124, 1890-1890.	1.4	0
147	Alterations of negative regulators of cytokine signalling in immunodeficiencyâ€related nonâ€Hodgkin lymphoma. Hematological Oncology, 2013, 31, 22-28.	1.7	14
148	Neurofibromatosis 1 Presenting with Multiple Duodenal Gists Associated with a Somatostatin-Producing D Cell Neoplasm. Endocrine Pathology, 2013, 24, 100-105.	9.0	7
149	<i>BRAF</i> (V600E) mutation analysis on liquidâ€based cytologyâ€processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathology, 2013, 121, 291-297.	2.4	104
150	Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients. Clinical Otolaryngology, 2013, 38, 248-253.	1.2	3
151	Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochirurgica, 2013, 155, 33-40.	1.7	27
152	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma. Neoplasia, 2013, 15, 773-IN27.	5.3	19
153	Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people. Thrombosis Research, 2013, 131, 238-243.	1.7	17
154	Detection of ectopic thyroid remnants: A serious diagnostic dilemma. When molecular biology and immunohistochemistry can solve the problem. Pathology Research and Practice, 2013, 209, 59-61.	2.3	13
155	Epigenetic silencing of <i>Id4</i> identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer, 2013, 119, 1004-1012.	4.1	42
156	Endothelial Progenitor Cells in HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e22-e23.	2.1	2
157	<i>MGA</i> , a suppressor of <i>MYC</i> , is recurrently inactivated in high risk chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1087-1090.	1.3	81
158	Inflammatory Fibroid Polyp of the Gallbladder Bearing a Platelet-Derived Growth Factor Receptor Alpha Mutation. Archives of Pathology and Laboratory Medicine, 2013, 137, 721-724.	2.5	19
159	The cytologic category of oncocytic (Hurthle) cell neoplasm mostly includes low-risk lesions at histology: an institutional experience. European Journal of Endocrinology, 2013, 169, 649-655.	3.7	30
160	Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. European Journal of Endocrinology, 2013, 168, 853-859.	3.7	62
161	Short Communication: Proangiogenic Hematopoietic Cells In Acute HIV Infection. AIDS Research and Human Retroviruses, 2013, 29, 307-310.	1.1	5
162	KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. British Journal of Cancer, 2013, 108, 115-120.	6.4	30

#	Article	IF	CITATIONS
163	Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia. Blood, 2013, 122, 860-860.	1.4	O
164	Hu/elav RNA-binding protein HuR regulates parathyroid hormone related peptide expression in human lung adenocarcinoma cells. Histology and Histopathology, 2013, 28, 1205-16.	0.7	3
165	Prognostic Relevance of c- <i>Myc</i> and <i>BMI1</i> Expression in Patients With Glioblastoma. American Journal of Clinical Pathology, 2012, 138, 390-396.	0.7	34
166	Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal "Immunological Niche―in Coeliac Disease After Gluten-Free Diet. Clinical and Translational Gastroenterology, 2012, 3, e28.	2.5	25
167	Cribriform-Morular Variant of Papillary Thyroid Carcinoma in an 8-Year-Old Girl. International Journal of Surgical Pathology, 2012, 20, 629-632.	0.8	15
168	von Hippel-Lindau Disease and Erythrocytosis. Journal of Clinical Oncology, 2012, 30, e137-e139.	1.6	16
169	Autosomal Dominant Ménétrierâ€ike Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 717-720.	1.8	9
170	Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood, 2012, 119, 2219-2227.	1.4	78
171	Difference in Clonality as a Tool for Differential Diagnosis of Primary Versus Secondary Lung Neoplasms. Journal of Thoracic Oncology, 2012, 7, 934-936.	1.1	2
172	Interleukin-6 plasma levels are modulated by a polymorphism in the <i>NF-κB1</i> gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2012, 53, 411-416.	1.3	36
173	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. International Journal of Cancer, 2012, 130, 3006-3010.	5.1	28
174	Images in Endocrine Pathology: Spindle Cell Lesion of the Thyroid Gland. Endocrine Pathology, 2012, 23, 132-134.	9.0	5
175	Different impact of <i><scp>NOTCH</scp>1</i> and <i><scp>SF</scp>3B1</i> mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. British Journal of Haematology, 2012, 158, 426-429.	2.5	90
176	Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. Inflammatory Bowel Diseases, 2012, 18, 439-448.	1.9	25
177	The Contact with MDS Endothelial Cells Alters the Pattern of Lineage-Specific Gene Expression During Normal Hematopoietic Differentiation. Blood, 2012, 120, 1718-1718.	1.4	0
178	Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood, 2011, 117, 2700-2707.	1.4	111
179	Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited. Neoplasia, 2011, 13, 1113-IN6.	<b>5.</b> 3	115
180	Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?. Clinical Colorectal Cancer, 2011, 10, 325-332.	2.3	78

#	Article	IF	Citations
181	Mutations of <i>CD79A</i> , <i>CD79B</i> and <i>EZH2</i> genes in immunodeficiencyâ€related nonâ€Hodgkin lymphomas. British Journal of Haematology, 2011, 152, 777-780.	2.5	16
182	Epigenetic silencing of <i>SOCS3</i> identifies a subset of prostate cancer with an aggressive behavior. Prostate, 2011, 71, 318-325.	2.3	71
183	Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer, 2011, 117, 162-174.	4.1	80
184	The Viral Load of Epstein–Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma. Clinical Cancer Research, 2011, 17, 2885-2892.	7.0	89
185	Endoscopic Ultrasound-Guided Fine-Needle Aspiration With Liquid-Based Cytologic Preparation in the Diagnosis of Primary Pancreatic Lymphoma. Pancreas, 2010, 39, 1299-1302.	1.1	31
186	Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. Aids, 2010, 24, 2443-2450.	2.2	33
187	Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica, 2010, 95, 65-70.	3.5	79
188	Genome wide DNAâ€profiling of HIVâ€related Bâ€cell lymphomas. British Journal of Haematology, 2010, 148, 245-255.	2.5	70
189	Thrombopoietin Receptor Activation, Thrombopoietin Mimetic Drugs, and Hereditary Thrombocytosis: Remarks on Bone Marrow Fibrosis. Journal of Clinical Oncology, 2010, 28, e317-e318.	1.6	9
190	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. Blood, 2010, 116, 2425-2425.	1.4	1
191	Quantitation of EBV-DNA In Peripheral Blood In Hodgkin Lymphoma: Associations with Other Biomarkers and Patient Characteristics. Blood, 2010, 116, 2678-2678.	1.4	0
192	Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Annals of Oncology, 2009, 20, 1408-1413.	1.2	110
193	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Clinical Cancer Research, 2009, 15, 4415-4422.	7.0	189
194	Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. Journal of Neuro-Oncology, 2009, 94, 235-242.	2.9	66
195	The mutant <i>JAK2</i> <sup>V617F</sup> allele burden in children with essential thrombocythemia. British Journal of Haematology, 2009, 145, 430-432.	2.5	10
196	Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leukemia Research, 2009, 33, 1352-1356.	0.8	31
197	Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica, 2009, 94, 1368-1374.	3.5	53
198	Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. International Journal of Cancer, 2008, 123, 1586-1592.	5.1	50

#	Article	IF	CITATIONS
199	Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. International Journal of Cancer, 2008, 123, 2955-2960.	5.1	74
200	Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World Journal of Surgical Oncology, 2008, 6, 111.	1.9	14
201	Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 8205-8212.	7.0	327
202	Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. American Journal of Clinical Pathology, 2008, 129, 472-477.	0.7	18
203	Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica, 2008, 93, 1178-1185.	3.5	26
204	A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica, 2008, 93, 1068-1071.	3.5	64
205	Hereditary Thrombocythemia: Clinical Characteristics, Biological Markers and Long-Term Follow-up in 4 Families Observed in a Single Hematologic Pediatric Center. Blood, 2008, 112, 5226-5226.	1.4	0
206	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Blood, 2008, 112, 778-778.	1.4	0
207	Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia. Journal of Clinical Oncology, 2007, 25, 1048-1053.	1.6	107
208	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2007, 48, 564-569.	1.3	14
209	Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood, 2007, 110, 354-359.	1.4	71
210	Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 1026-1030.	1.6	11
211	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Annals of Oncology, 2007, 18, 1376-1381.	1.2	47
212	The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood, 2007, 110, 3384-3386.	1.4	50
213	Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. Leukemia, 2007, 21, 2552-2554.	7.2	13
214	Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. Journal of Infection, 2007, 54, 298-306.	3.3	20
215	Overexpression of <i>PRV-1</i> Gene in Polycythemia Rubra Vera and Essential Thrombocythemia. , 2006, 125, 265-274.		5
216	Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. British Journal of Cancer, 2006, 95, 1108-1113.	6.4	69

#	Article	IF	CITATIONS
217	ISSQoL: A New Questionnaire for Evaluating the Quality of Life of People Living with HIV in the HAART Era*. Quality of Life Research, 2006, 15, 377-390.	3.1	27
218	DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica, 2006, 91, 1252-6.	3.5	10
219	Role of <i>p16/INK4a</i> i>in Gastrointestinal Stromal Tumor Progression. American Journal of Clinical Pathology, 2004, 122, 35-43.	0.7	52
220	The PRV-1 gene expression in essential thrombocythemia. Blood, 2004, 104, 2995-2996.	1.4	7
221	Role of p16/INK4a in Gastrointestinal Stromal Tumor Progression. American Journal of Clinical Pathology, 2004, 122, 35-43.	0.7	25
222	Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes and Cancer, 2003, 38, 91-96.	2.8	51
223	Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis. Leukemia, 2003, 17, 919-924.	7.2	55
224	Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia. Journal of Clinical Oncology, 2002, 20, 4249-4254.	1.6	51
225	Relationship Between Gastric Localization of Hepatitis C Virus and Mucosa-associated Lymphoid Tissue in Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology, 2002, 37, 1126-1132.	1.5	6
226	Characterization of Epstein–Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. AIDS Research and Human Retroviruses, 2002, 18, 19-26.	1.1	16
227	Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. European Journal of Cancer, 2002, 38, 527-534.	2.8	36
228	Possible involvement of hMLH1, p16INK4a and PTEN in the malignant transformation of endometriosis. International Journal of Cancer, 2002, 102, 398-406.	5.1	128
229	Absence of structural mutations of the BAK gene in B cell lymphomas. Haematologica, 2002, 87, 661-2.	3.5	3
230	Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood, 2001, 98, 495-497.	1.4	42
231	Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 159-165.	2.8	24
232	In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. International Journal of Cancer, 2000, 88, 895-901.	5.1	40
233	Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 519-526.	0.4	37
234	Epstein-Barr Virus Infection Is Predictive of CNS Involvement in Systemic AIDS-Related Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2000, 18, 3325-3330.	1.6	92